14.7 C
New York

Elemind: Wearable AI offers ‘electric medicine’ via brain stimulation

Published:

A team of scientists, doctors, and entrepreneurs has secured $12 million in initial funding for a novel noninvasive health wearable fueled by artificial intelligence (AI).

Developed by Elemind, a health tech firm, this wearable neurotechnology system employs unique algorithms and AI to enhance health through brainwave stimulation, providing benefits without the usual side effects of medications. After successfully demonstrating its effectiveness through several studies, the program has attracted $12 million in seed investment, as announced on Tuesday (Feb. 6).

How does Elemind function?

The device operates by monitoring individual brainwaves and delivering real-time stimulation with personalized responses utilizing its AI capabilities. This precise brainwave guidance offers a more specific approach compared to traditional medications, resulting in fewer side effects.

According to Meredith Perry, Elemind’s CEO and co-founder, “Chemical drugs impact the entire body, often resulting in adverse effects. Elemind provides a non-chemical, direct, and on-demand solution that adjusts and learns for each person. We are the first and only company capable of precisely guiding and redirecting brainwaves in real-time.”

Elemind describes its methodology as “electric medicine”, developed in collaboration with renowned research institutions such as the Massachusetts Institute of Technology (MIT), Imperial College London, Harvard Medical School, and the University of California at Berkeley. Various applications have been adapted for the platform, allowing for diverse uses through wearable technology.

Preliminary clinical trials have shown Elemind’s technology to be effective in inducing sleep up to 74% faster, reducing tremors after just 30 seconds of stimulation, and enhancing memory. The Elemind team anticipates a positive impact on various neurological conditions in the future.

As a device for general well-being, Elemind’s initial product is not regulated by the FDA. With early investments from Village Global, LDV Partners, and other financial entities, the company aims to create more wearable solutions for its neurotech platform.

Featured image: Pexels

Related articles

Recent articles